Literature DB >> 8276176

Prevention of ischemia/reperfusion injury in the rat liver by atrial natriuretic peptide.

M Bilzer1, R Witthaut, G Paumgartner, A L Gerbes.   

Abstract

BACKGROUND/AIMS: Atrial natriuretic peptide (ANP) protects against hypoxia/reoxygenation-induced damage of cultured hepatocytes, thus suggesting a therapeutic potential in the liver. Therefore, the effects of ANP on hepatic ischemia/reperfusion injury after warm ischemia were studied.
METHODS: Livers of male Sprague-Dawley rats subjected to 60 minutes of warm ischemia at 37 degrees C were perfused in the presence or absence of 200 and 20 nmol/L ANP.
RESULTS: Sinusoidal lactate dehydrogenase efflux increased to 2000 +/- 264 and 126 +/- 50 mU.min-1.g liver-1 after 1 minute and 60 minutes of reperfusion, but it only increased to 1240 +/- 160 and 22 +/- 16 mU.min-1.g liver-1 in the presence of 200 nmol/L ANP during the preischemic and postischemic perfusion period. The postischemic bile flow (0.67 +/- 0.18 microL.min-1.g liver-1) was significantly improved with 200 nmol/L ANP (0.92 +/- 0.05) and showed a linear correlation to biliary glutathione excretion. In contrast, 20 nmol/L ANP had no protective effects. Administration of 200 nmol/L ANP during the preischemic perfusion period alone (but not after starting reperfusion) markedly preserved postischemic liver function.
CONCLUSIONS: Continuous ANP administration or ANP pretreatment alone prevents hepatic ischemia/reperfusion injury, possibly because of influences on intracellular signal transduction processes. The correlation between bile flow and biliary glutathione excretion supports the hypothesis that biliary glutathione transport is one of the osmotic driving forces in postischemic bile formation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276176     DOI: 10.1016/s0016-5085(94)94961-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Hepatocyte cytoskeleton during ischemia and reperfusion--influence of ANP-mediated p38 MAPK activation.

Authors:  Melanie Keller; Alexander L Gerbes; Stefanie Kulhanek-Heinze; Tobias Gerwig; Uwe Grutzner; Nico van Rooijen; Angelika M Vollmar; Alexandra K Kiemer
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

2.  Effect of atrial natriuretic peptide on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model.

Authors:  Katsumi Kobayashi; Kiyohiro Oshima; Masato Muraoka; Takahiko Akao; Osamu Totsuka; Hisashi Shimizu; Hiroaki Sato; Kazumi Tanaka; Kenjiro Konno; Koshi Matsumoto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

3.  Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver.

Authors:  A M Vollmar; G Paumgartner; A L Gerbes
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  Stimulation of p38 MAPK by hormonal preconditioning with atrial natriuretic peptide.

Authors:  Alexandra K Kiemer; Stefanie Kulhanek-Heinze; Tobias Gerwig; Alexander L Gerbes; Angelika M Vollmar
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

5.  Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) dampens hepatic ischemia-reperfusion injury.

Authors:  David Köhler; Philipp Birk; Klemens König; Andreas Straub; Therese Eldh; Julio C Morote-Garcia; Peter Rosenberger
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

Review 6.  Science review: natriuretic peptides in critical illness.

Authors:  Rochus Witthaut
Journal:  Crit Care       Date:  2004-06-17       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.